Paris (AFP)
Spending on health products, primarily for drugs, will increase "by the order of one billion euros" in the Social Security budget for 2022 which will be presented at the end of the week, said Monday. Ministry of Health to AFP.
The purse strings are loosened for the pharmaceutical industry, translation of the "Health Innovation 2030" plan presented at the end of June by Emmanuel Macron.
The Head of State had promised an average increase of 2.4% per year until 2024 in expenses reimbursed by Health Insurance.
"We will be above" in 2022, with growth "of the order of one billion euros" for drugs and medical devices, assures the cabinet of Olivier Véran.
In the morning, the Minister of Health visited the cell and gene therapy production site CellForCure (Novartis group), to show that "France knows how to welcome companies that develop innovative products", explains his entourage.
Of which act: the 2022 budget will include 400 million euros of "new measures", starting with a doubling (from 150 to 300 million) of the credits granted to laboratories which invest in production or research, in France but also elsewhere in the European Union.
The Social Security financing bill (PLFSS), which will be unveiled on Friday, will also include articles aimed at "accelerating the marketing of innovative drugs" and guaranteeing their "100% coverage at the hospital "- including in case of" moderate "or" minor "improvement.
This boost to innovation will not prevent the government from trying, as it does every year, to curb the "very dynamic trend growth" in spending on health products.
If the extent of the savings targeted is not yet known, the Health Insurance proposed in June to achieve nearly 500 million euros.
In the end, the envelope will still grow by a billion, not counting the 800 million intended for biotherapies by 2025, as part of the fourth program of investments for the future (PIA4).
© 2021 AFP